Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis
BackgroundCEUS LI-RADS and CT/MRI LI-RADS have been used in clinical practice for several years. However, there is a lack of evidence-based study to compare the proportion of hepatocellular carcinomas (HCCs) in each category and the distribution of HCCs of these two categorization systems.PurposeThe...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.873913/full |
| _version_ | 1818313000628518912 |
|---|---|
| author | Yan Zhou Yan Zhou Zhengyi Qin Jianmin Ding Lin Zhao Ying Chen Fengmei Wang Fengmei Wang Xiang Jing |
| author_facet | Yan Zhou Yan Zhou Zhengyi Qin Jianmin Ding Lin Zhao Ying Chen Fengmei Wang Fengmei Wang Xiang Jing |
| author_sort | Yan Zhou |
| collection | DOAJ |
| description | BackgroundCEUS LI-RADS and CT/MRI LI-RADS have been used in clinical practice for several years. However, there is a lack of evidence-based study to compare the proportion of hepatocellular carcinomas (HCCs) in each category and the distribution of HCCs of these two categorization systems.PurposeThe purpose of this study was to compare the proportion of HCCs between corresponding CEUS LI-RADS and CT/MRI LI-RADS categories and the distribution of HCCs and non-HCC malignancies in each category.MethodsWe searched PubMed, Embase, and Cochrane Central databases from January 2014 to December 2021. The proportion of HCCs and non-HCC malignancies and the corresponding sensitivity, specificity, accuracy, diagnostic odds ratio (DOR), and area under the curve (AUC) of the LR-5 and LR-M categories were determined using a random-effect model.ResultsA total of 43 studies were included. The proportion of HCCs in CEUS LR-5 was 96%, and that in CECT/MRI LR-5 was 95% (p > 0.05). The proportion of non-HCC malignancy in CEUS LR-M was lower than that of CT/MRI LR-M (35% vs. 58%, p = 0.01). The sensitivity, specificity, and accuracy of CEUS LR-5 for HCCs were 73%, 92%, and 78%, respectively, and of CT/MRI LR-5 for HCCs, 69%, 92%, and 76%, respectively.ConclusionWith the upshift of the LI-RADS category, the proportion of HCCs increased. CEUS LR-3 has a lower risk of HCCs than CT/MRI LR-3. CEUS LR-5 and CT/MRI LR-5 have a similar diagnostic performance for HCCs. CEUS LR-M has a higher proportion of HCCs and a lower proportion of non-HCC malignancies compared with CT/MRI LR-M. |
| first_indexed | 2024-12-13T08:26:47Z |
| format | Article |
| id | doaj.art-487992bfc31e4316b37058ab8831c70d |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T08:26:47Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-487992bfc31e4316b37058ab8831c70d2022-12-21T23:53:52ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-03-011210.3389/fonc.2022.873913873913Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-AnalysisYan Zhou0Yan Zhou1Zhengyi Qin2Jianmin Ding3Lin Zhao4Ying Chen5Fengmei Wang6Fengmei Wang7Xiang Jing8School of Medicine, Nankai University, Tianjin, ChinaDepartment of Ultrasound, Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Third Central Hospital, Tianjin, ChinaDepartment of Ultrasound, Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Third Central Hospital, Tianjin, ChinaDepartment of Ultrasound, Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Third Central Hospital, Tianjin, ChinaDepartment of Ultrasound, Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Third Central Hospital, Tianjin, ChinaDepartment of Ultrasound, Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Third Central Hospital, Tianjin, ChinaSchool of Medicine, Nankai University, Tianjin, ChinaDepartment of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin, ChinaDepartment of Ultrasound, Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Third Central Hospital, Tianjin, ChinaBackgroundCEUS LI-RADS and CT/MRI LI-RADS have been used in clinical practice for several years. However, there is a lack of evidence-based study to compare the proportion of hepatocellular carcinomas (HCCs) in each category and the distribution of HCCs of these two categorization systems.PurposeThe purpose of this study was to compare the proportion of HCCs between corresponding CEUS LI-RADS and CT/MRI LI-RADS categories and the distribution of HCCs and non-HCC malignancies in each category.MethodsWe searched PubMed, Embase, and Cochrane Central databases from January 2014 to December 2021. The proportion of HCCs and non-HCC malignancies and the corresponding sensitivity, specificity, accuracy, diagnostic odds ratio (DOR), and area under the curve (AUC) of the LR-5 and LR-M categories were determined using a random-effect model.ResultsA total of 43 studies were included. The proportion of HCCs in CEUS LR-5 was 96%, and that in CECT/MRI LR-5 was 95% (p > 0.05). The proportion of non-HCC malignancy in CEUS LR-M was lower than that of CT/MRI LR-M (35% vs. 58%, p = 0.01). The sensitivity, specificity, and accuracy of CEUS LR-5 for HCCs were 73%, 92%, and 78%, respectively, and of CT/MRI LR-5 for HCCs, 69%, 92%, and 76%, respectively.ConclusionWith the upshift of the LI-RADS category, the proportion of HCCs increased. CEUS LR-3 has a lower risk of HCCs than CT/MRI LR-3. CEUS LR-5 and CT/MRI LR-5 have a similar diagnostic performance for HCCs. CEUS LR-M has a higher proportion of HCCs and a lower proportion of non-HCC malignancies compared with CT/MRI LR-M.https://www.frontiersin.org/articles/10.3389/fonc.2022.873913/fullcontrast-enhanced ultrasoundcontrast-enhanced magnetic resonance imagingContrast-enhanced computed tomographyhepatocellular carcinomaLiver Imaging Reporting and Data System |
| spellingShingle | Yan Zhou Yan Zhou Zhengyi Qin Jianmin Ding Lin Zhao Ying Chen Fengmei Wang Fengmei Wang Xiang Jing Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis Frontiers in Oncology contrast-enhanced ultrasound contrast-enhanced magnetic resonance imaging Contrast-enhanced computed tomography hepatocellular carcinoma Liver Imaging Reporting and Data System |
| title | Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis |
| title_full | Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis |
| title_fullStr | Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis |
| title_full_unstemmed | Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis |
| title_short | Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis |
| title_sort | risk stratification and distribution of hepatocellular carcinomas in ceus and ct mri li rads a meta analysis |
| topic | contrast-enhanced ultrasound contrast-enhanced magnetic resonance imaging Contrast-enhanced computed tomography hepatocellular carcinoma Liver Imaging Reporting and Data System |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.873913/full |
| work_keys_str_mv | AT yanzhou riskstratificationanddistributionofhepatocellularcarcinomasinceusandctmriliradsametaanalysis AT yanzhou riskstratificationanddistributionofhepatocellularcarcinomasinceusandctmriliradsametaanalysis AT zhengyiqin riskstratificationanddistributionofhepatocellularcarcinomasinceusandctmriliradsametaanalysis AT jianminding riskstratificationanddistributionofhepatocellularcarcinomasinceusandctmriliradsametaanalysis AT linzhao riskstratificationanddistributionofhepatocellularcarcinomasinceusandctmriliradsametaanalysis AT yingchen riskstratificationanddistributionofhepatocellularcarcinomasinceusandctmriliradsametaanalysis AT fengmeiwang riskstratificationanddistributionofhepatocellularcarcinomasinceusandctmriliradsametaanalysis AT fengmeiwang riskstratificationanddistributionofhepatocellularcarcinomasinceusandctmriliradsametaanalysis AT xiangjing riskstratificationanddistributionofhepatocellularcarcinomasinceusandctmriliradsametaanalysis |